Overview

Pilot Study to Assess the Effects of AV608 on Irritable Bowel Syndrome

Status:
Terminated
Trial end date:
2007-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the effects of AV608, a neurokinin 1 (NK-1) antagonist, in subjects with Irritable Bowel Syndrome.
Phase:
Phase 1
Details
Lead Sponsor:
Avera Pharmaceuticals
Collaborator:
University of California, Los Angeles